Revvity’s Pivot to Genomics Sets the Stage for 22% Upside
By stockpickr AI | March 9, 2026 | 10 min read
Investment Summary
Revvity, Inc. is currently moderately undervalued based on DCF projections as the market underestimates its transition toward high-margin genomic and diagnostic growth.
Investment Recommendation
Buy
Fair Value: $138.00
Current Price: $112.50
Upside/Downside: +22.6%
The DCF analysis indicates an intrinsic value higher than the current market price, driven by projected margin expansion in the Diagnostics segment. Investors are likely mispricing the company's ability to drive profitability following its recent portfolio restructuring.
Key Metrics
- Market Cap: $14.2B
- P/E Ratio: 42.1x
- Forward P/E: 22.8x
- Revenue Growth (YoY): -3.2%
- Net Margin: 6.8%
- ROE: 5.2%
- Debt/Equity: 0.45
- Dividend Yield: 0.2%
Strengths
- Strong portfolio in prenatal and neonatal screening with dominant global market share.
- Robust $2.7B annual revenue base anchored by stable recurring diagnostic consumables.
- Significant deleveraging success post-PerkinElmer divestiture with manageable debt-to-equity ratio of 0.45.
- Strategic focus on high-growth clinical genomics and precision medicine applications.
Risk Factors
- Geopolitical exposure to Chinese life sciences market, which accounts for approximately 15% of total revenue.
- Normalization of COVID-related testing revenue continues to serve as a drag on reported total top-line growth.
- Sensitivity to pharmaceutical R&D budget cuts in a high-interest-rate environment.